Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Mallinckrodt PLC MNKTQ

Mallinckrodt plc develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Current News (OTCPK:MNKTQ)

Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at the 2024 European Association for the Study of the Liver (EASL) Congress

PR Newswire June 5, 2024

Mallinckrodt plc Reports First Quarter 2024 Financial Results and Reaffirms Full Year Guidance

PR Newswire May 9, 2024

Mallinckrodt Announces Journal Publication of Real-World Data on Acthar® Gel (repository corticotropin injection) to Treat Symptomatic Sarcoidosis in African American and Non-African American Patients

PR Newswire March 11, 2024

Mallinckrodt Announces Board of Directors and Leadership Updates

PR Newswire February 2, 2024

Mallinckrodt Presents New Data on TERLIVAZ® (terlipressin) for Injection at the Society of Critical Care Medicine (SCCM) 2024 Critical Care Congress

PR Newswire January 22, 2024

Mallinckrodt Completes Financial Restructuring and Irish Examinership Proceedings and Emerges From Chapter 11

PR Newswire November 14, 2023

High Court of Ireland Confirms Mallinckrodt Scheme of Arrangement

PR Newswire November 10, 2023

Mallinckrodt to Present Breadth of Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Association for the Study of Liver Diseases (AASLD) 2023 Liver Meeting

PR Newswire November 8, 2023

Mallinckrodt plc (in Examinership) Reports Third Quarter 2023 Financial Results

PR Newswire November 7, 2023

Opinion & Analysis (OTCPK:MNKTQ)

No current opinion is available.

Bullboard Posts (OTCPK:MNKTQ)

MNK....big trader yesterday..52 mil shs up 200%

Now trading large in PM trading ...$1.72 now And to think u could have bot this for 44 cents 2 days ago ...LoL
Iseneschal - July 27, 2023